The use of adrenocorticotrophic hormone as a potential biomarker of pituitary pars intermedia dysfunction in horses

Veterinary Journal

Volumn 185, Issue 1, 2010, Pages 58-61

  Lee, Zuo Yen ^a   Zylstra, Robert ^a   Haritou, Susan J A ^a  

^a BioCity Nottingham   (United Kingdom)

Author keywords

Adrenocorticotrophic hormone (ACTH); Biomarker; Circadian; Laminitis; Pituitary pars intermedia dysfunction (PPID)

Indexed keywords

BIOLOGICAL MARKER; CORTICOTROPIN;

AGED; ANIMAL EXPERIMENT; ARTICLE; BLOOD ANALYSIS; CIRCADIAN RHYTHM; CIRCANNUAL RHYTHM; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DISEASE COURSE; HORMONE DETERMINATION; HORMONE RESPONSE; HORMONE SYNTHESIS; HORSE DISEASE; HYPOPHYSIS DISEASE; NONHUMAN; PHOTOPERIODICITY; PITUITARY PARS INTERMEDIA DYSFUNCTION; SEASONAL VARIATION; ANIMAL; BLOOD; CASE CONTROL STUDY; FEMALE; HORSE; HORSE DISEASES; HYPOPHYSIS INTERMEDIATE LOBE; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PITUITARY DISEASES; SEASON; VETERINARY;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CIRCADIAN RHYTHM; FEMALE; HORSE DISEASES; HORSES; MALE; PITUITARY DISEASES; PITUITARY GLAND, INTERMEDIATE; SEASONS;

ANIMALIA; EQUIDAE;

EID: 77953676067     PISSN: 10900233     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tvjl.2010.04.014     Document Type: Article

References (19)

1. Alexander S.L., Irvine C.H.G., Donald R.A. Dynamics of the regulation of the hypothalamo-pituitary-adrenal (HPA) axis determined using a nonsurgical method for collecting pituitary venous blood from horses. Frontiers in Neuroendocrinology 2002, 17:1-50.
2. Bailey S.R., Marr C.M., Elliot J. Current research and theories on the pathogenesis of acute laminitis in the horse. The Veterinary Journal 2004, 167:129-142.
3. Beech J., Boston R.C., McFarlane D., Lindborg S. Evaluation of plasma ACTH, alpha-melanocyte-stimulating hormone, and insulin concentrations during various photoperiods in clinically normal horses and ponies and those with pituitary pars intermedia dysfunction. Journal of the American Veterinary Medical Association 2009, 15:715-722.
4. Couetil L., Paradis M.R., Knoll J. Plasma adrenocorticotropin concentration in healthy horses and in horses with clinical signs of hyperadrenocorticism. Journal of Veterinary Internal Medicine/American College of Veterinary Internal Medicine 1996, 10:1-6.
5. Cudd T.A., LeBlanc M., Silver M., Norman W., Madison J., Keller-Wood M., Wood C.E. Ontogeny and ultradian rhythms of adrenocorticotropin and cortisol in the late-gestation fetal horse. Journal of Endocrinology 1995, 144:271-283.
6. Divers T.J. Endocrine testing in horses: metabolic syndrome and Cushing's disease. Journal of Equine Veterinary Science 2008, 28:315-316.
7. Donaldson M.T., LaMonte B.H., Morressey P., Smith G., Beech J. Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (equine Cushing's disease). Journal of Veterinary Internal Medicine 2002, 16:742-746.
8. Donaldson M.T., McDonnell S.M., Schanbacher B.J., Lamb S.V., McFarlane D., Beech J. Variation in plasma adrenocorticotropic hormone concentration and dexamethasone suppression test results with season, age, and sex in healthy ponies and horses. Journal of Veterinary Internal Medicine 2005, 19:217-222.
9. Haritou S.J., Zylstra R., Ralli C., Turner S., Tortonese D.J. Seasonal changes in circadian peripheral plasma concentrations of melatonin, serotonin, dopamine and cortisol in aged horses with Cushing's disease under natural photoperiod. Journal of Neuroendocrinology 2008, 20:988-996.
10. Hoffman R.M., Wilson J.A., Kronfeld D.S. Hydrolyzable carbohydrates in pasture, hay, and horse feeds: direct assay and seasonal variation. Journal of Animal Science 2001, 79:500-506.
11. Knottenbelt D.C. Saunders Equine Formulary 2006, Saunders Elsevier, Liverpool, UK. fourth ed.
12. McFarlane D. Advantages and limitations of the equine disease, pituitary pars intermedia dysfunction, as a model of spontaneous dopaminergic neurodegenerative disease. Ageing Research Reviews 2007, 6:54-63.
13. McFarlane, D., Donaldson, M.T., Saleh, T.M., Cribb, A.E., 2003. The role of dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction (equine Cushing's disease). In: Proceedings of the 49th Annual Convention of the American Association of Equine Practitioners, New Orleans, USA, pp. 233-237.
14. Muñoz M.C., Doreste F., Ferrer O., González J., Montoya J.A. Pergolide treatment for Cushing's syndrome in a horse. Veterinary Record 1996, 139:41-43.
15. Orth D.N., Holscher M.A., Wilson M.G., Nicholson W.E., Plue R.E., Mount C.D. Equine Cushing's disease: plasma immunoreactive proopiolipomelanocortin peptide and cortisol levels basally and in response to diagnostic tests. Endocrinology 1982, 110:1430-1441.
16. Perkins G.A., Lamb S., Erb H.N., Shanbacher B., Nydam D.V., Divers T.J. Plasma adrenocorticotropin (ACTH) concentrations and clinical response in horses treated for equine Cushing's diseases with cyproheptatidine or pergolide. Equine Veterinary Journal 2002, 34:679-685.
17. Robie S.M., Janson C.H., Smith S.C., O'Connor J.T. Equine serum lipids: serum lipids and glucose in Morgan and Thoroughbred horses and Shetland Ponies. American Journal of Veterinary Research 1975, 36:1705-1708.
18. Van der Kolk J.H., Wensing T., Kalsbeek H.C., Breuking H.J. Laboratory diagnosis of equine pituitary pars intermedia adenoma. Domestic Animal Endocrinology 1995, 12:35-39.
19. Watts K.A. A review of unlikely sources of excess carbohydrate in equine diets. Journal of Equine Veterinary Science 2005, 25:338-344.